Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice
SM Cahalan, PJ Gonzalez-Cabrera… - Nature chemical …, 2011 - nature.com
SM Cahalan, PJ Gonzalez-Cabrera, G Sarkisyan, N Nguyen, MT Schaeffer, L Huang…
Nature chemical biology, 2011•nature.comAbstract Sphingosine 1-phosphate receptor 1 (S1P1) is critical for lymphocyte recirculation
and is a clinical target for treatment of multiple sclerosis. By generating a short-duration
S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, we
elucidate physiological and agonist-perturbed changes in expression of S1P1 at a
subcellular level in vivo. We demonstrate differential downregulation of S1P1 on
lymphocytes and endothelia after agonist treatment.
and is a clinical target for treatment of multiple sclerosis. By generating a short-duration
S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, we
elucidate physiological and agonist-perturbed changes in expression of S1P1 at a
subcellular level in vivo. We demonstrate differential downregulation of S1P1 on
lymphocytes and endothelia after agonist treatment.
Abstract
Sphingosine 1-phosphate receptor 1 (S1P1) is critical for lymphocyte recirculation and is a clinical target for treatment of multiple sclerosis. By generating a short-duration S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, we elucidate physiological and agonist-perturbed changes in expression of S1P1 at a subcellular level in vivo. We demonstrate differential downregulation of S1P1 on lymphocytes and endothelia after agonist treatment.
nature.com